Method of administration

**IV administration**

The reconstituted solution is administered as a 3-5 second bolus intravenous injection through a peripheral or central intravenous catheter followed by a flush with sodium chloride 9 mg/ml (0.9%) solution for injection.

**SC administration**

The reconstituted solution is administered subcutaneously on the thighs (right or left, proximal and distal sites) or abdomen (right or left, upper or lower quadrant). Injection sites should be rotated for successive injections.

**DOSAGE & ADMINISTRATION**

**Adults and Elderly:**

- **Hematopoietic stem cell transplant.** With dexamethasone, or patients not eligible for high-dose chemotherapy with rituximab, cyclophosphamide, doxorubicin and thalidomide (50 mg): 4 × 21-days treatment cycles. With oral dexamethasone (40 mg): 5, 8, 9, 11, and 12 of VELCADE treatment cycle.

- **Combination with oral dexamethasone (40 mg):**
  - Previously untreated multiple myeloma patients eligible for haematopoietic stem cell transplantation: 2.1 2.73 2.73 1.09
  - Previously treated multiple myeloma patients eligible for haematopoietic stem cell transplant: twice the above dose, then possible increase to 1.0 mg/m² or reduction to 0.65 mg/m².

**Posology modifications**

At least 72 hours between consecutive doses.

**MONITORING & PRECAUTIONS**

- Renal impairment: 1.6 2.08 2.08 0.83
- Hepatic impairment: 1.0 1.1 1.2 1.3
- Impaired renal function: see SmPC.
- Impaired hepatic function: see SmPC.
- Impaired cardiac function: see SmPC.
- Impaired bone marrow function: see SmPC.
- Impaired pulmonary function: see SmPC.
- Impaired endocrine function: see SmPC.
- Impaired renal and hepatic function: see SmPC.

**INTERACTIONS**

- **Contraindications:**
  - Hypersensitivity to VELCADE®.
  - **Contraindication for IV use (in ml) volume with** 1.3 mg/m² body surface area.

**Adverse events**

- **Common:**
  - Anaemia, asthenia, constipation, fatigue, pyrexia, dyspepsia, abdominal pain, insomnia, depression, dysaesthesia, neuralgia, nausea, vomiting, diarrhoea, flatulence, hepatic enzyme abnormality, erythema, dry skin, muscle spasms, pain in extremity, oedema (inc peripheral), visual impairment, cardiac fibrillation (inc atrial), arrhythmia, cardiac failure (inc heart failure), pulmonary oedema (inc acute respiratory distress syndrome), pneumonia, leukopenia, lymphopenia, dehydration, fever, chills, malaise, weight decreased.

- **Less Common:**
  - Hypotension, hypertension, dyspnoea, upper/lower respiratory tract infection, acute respiratory distress syndrome, cardiac valve disorders, sinus arrest, cerebrovascular accident, deep vein thrombosis, thrombophlebitis, phlebitis, angina, myocardial infarction, myocardial ischaemia, tachycardia, bradycardia, ventricular fibrillation, atrial fibrillation, arrhythmia, angina pectoris, chest pain, diabetes mellitus, hypoglycaemia, hyperglycaemia, hyperuricaemia, hyperlipidaemia, dermatitis, musculoskeletal pain, abdominal pain, peripheral oedema, palpitations, dyspnoea, rash, malaise, weight increased.

- **Rare:**
  - Anaphylactic shock/reaction, hearing impaired (up to and including profound hearing loss), herpes zoster virus reactivation: intrathecally.

**Employed in:** Allergic reaction.

**Prescribing information can be found within.**